Log in to your Inderes Free account to see all free content on this page.
CellaVision
238.5 SEK +2.36%1,505 investors are following this company
CellaVision is active in medical technology. The company's operations develop and market image analysis systems for diagnosing blood and other body fluids. The products are intended to replace traditional microscope analysis. Operations are conducted on a global level, primarily in the Nordic countries, Europe and North America, where customers consist of research institutes. The head office is located in Lund.
Revenue
677.29M
EBIT %
24.66 %
P/E
43.68
Dividend yield-%
0.94 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CEVI
Daily low / high price
233 / 239.5
SEK
Market cap
5.69B SEK
Turnover
2.54M SEK
Volume
11K
Latest videos
Financial calendar
Interim report
25.04.2024
General meeting
03.05.2024
Annual dividend
06.05.2024
Interim report
19.07.2024
Interim report
24.10.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
William Demant Invest | 19.9 % | 19.9 % |
Grenlunden CEVI AB | 10.0 % | 10.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
CellaVision publishes its 2023 Annual and Sustainability Report
CellaVision, Audiocast with teleconference, Q1, 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio